Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

1 year ago

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21,…

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

1 year ago

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

1 year ago

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

1 year ago

Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better…

CTT Pharmaceuticals Holdings, Inc. Successfully Completes 2 Year PCAOB Audit

1 year ago

TAMPA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- CTT Pharmaceuticals Holdings, Inc. (OTC: CTTH), is pleased to announce that the…

NewGenIvf Announces Filing of 2023 Annual Report with the SEC

1 year ago

Total Revenues Reach US$5.1 MillionGross Profit Increases by 9.4% to US$1.7 MillionNet Income of US$0.1 million BANGKOK, Thailand, Aug. 21,…

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

1 year ago

Patented personalized medicine approach for patient dosing for autologous cell therapyExpected to meaningfully enhance clinical experience and market opportunity SUNNYVALE,…

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

1 year ago

──Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC)── ──Establishes…

OKYO Pharma Announces Chairman Acquires Shares

1 year ago

LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing…

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

1 year ago

Study supports BioStem’s strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the…